Table 2.
Subgroup analysis of incidence rate of adverse events, sever adverse events and death after SARS-CoV-2 vaccination, by study population, vaccine type, and population size
| No. cohorts | Incidence rate of adverse events (%) (95% CI) | I2 (%) | P value for heterogeneity | P value for subgroup differences | Weight (%) | |
|---|---|---|---|---|---|---|
| Overall | 31 | 1.5 (1.4–1.6) | 100.0 | < 0.001 | 100 | |
| Study population | < 0.001 | |||||
| General population | 10 | 1.0 (0.9–1.0) | 100.0 | < 0.001 | 98.92 | |
| Healthcare workers | 6 | 53.2 (28.4–77.9) | 99.8 | < 0.001 | 0.80 | |
| Patients | 15 | 45.7 (33.8–57.6) | 97.2 | < 0.001 | 0.28 | |
| Vaccine type | < 0.001 | |||||
| BNT162b2 | 17 | 49.6 (21.8–77.4) | 99.9 | < 0.001 | 23.57 | |
| AZD1222 | 4 | 79.6 (60.8–98.3) | 99.1 | < 0.001 | 0.49 | |
| mRNA-1273 | 1 | 50.0 (34.9–65.1) | .. | .. | 0.01 | |
| CoronaVac | 3 | 30.8 (7.8–53.8) | 99.7 | < 0.001 | 0.63 | |
| Ad26.COV2.S | 1 | 0.2 (0.2–0.2) | .. | .. | 25.03 | |
| Gam-COVID-Vac | 1 | 71.3 (67.9–74.7) | .. | .. | 0.08 | |
| BBIBP-CorV | 1 | 29.4 (24.8–34.0) | .. | .. | 0.04 | |
| Any | 3 | 0.0 (0.0–0.1) | 100.0 | < 0.001 | 50.15 | |
| Population size | < 0.001 | |||||
| < 1000 | 24 | 57.6 (47.9–67.4) | 99.2 | < 0.001 | 1.41 | |
| 1000–10 000 | 3 | 29.1 (3.3–54.9) | 99.8 | < 0.001 | 0.75 | |
| 10 000–100 000 | 1 | 0.4 (0.3–0.4) | .. | .. | 22.74 | |
| > 100 000 | 3 | 0.1 (0.0–0.1) | 100.0 | < 0.001 | 75.11 | |
| No. cohorts | Incidence rate of severe adverse events (per 10 000) (95% CI) | I2 (%) | P value for heterogeneity | P value for subgroup differences | Weight (%) | |
|---|---|---|---|---|---|---|
| Overall | 15 | 0.4 (0.2–0.5) | 98.2 | < 0.001 | 100 | |
| Study population | < 0.001 | |||||
| General population | 9 | 0.4 (0.2–0.5) | 98.9 | < 0.001 | 84.53 | |
| Healthcare workers | 2 | 127.2 (62.7–191.8) | 36.1 | 0.211 | 0.01 | |
| Patients | 4 | 22.5 (0.0–72.6) | 77.7 | 0.004 | 15.46 | |
| Vaccine type | < 0.001 | |||||
| BNT162b2 | 5 | 8.1 (0.0–17.8) | 98.2 | < 0.001 | 7.71 | |
| mRNA-1273 | 2 | 4.2 (0.0–16.3) | 43.9 | 0.182 | 0.83 | |
| CoronaVac | 1 | 104.8 (53.7–156.0) | .. | .. | 0.01 | |
| Ad26.COV2.S | 1 | 0.4 (0.4–0.5) | .. | .. | 18.84 | |
| Gam-COVID-Vac | 1 | 175.7 (77.2–274.2) | .. | .. | 0.01 | |
| Any | 5 | 0.3 (0.2–0.5) | 99.1 | < 0.001 | 72.60 | |
| Population size | 0.030 | |||||
| < 1000 | 4 | 90.4 (0.0–193.5) | 82.7 | 0.001 | 0.01 | |
| 1000–10 000 | 3 | 336.6 (41.4–631.8) | 99.0 | < 0.001 | 0.01 | |
| 10 000–100 000 | 3 | 1.0 (0.0–2.2) | 73.3 | 0.024 | 8.54 | |
| > 100 000 | 5 | 0.4 (0.2–0.5) | 99.2 | < 0.001 | 91.45 | |
| No. cohorts | Incidence rate of death after vaccination (per 10 000) (95% CI) | I2 (%) | P value for heterogeneity | P value for subgroup differences | Weight (%) | |
|---|---|---|---|---|---|---|
| Overall | 5 | 0.1 (0.1–0.2) | 87.6 | < 0.001 | 100 | |
| Study population | 0.549 | |||||
| General population | 3 | 0.1 (0.1–0.1) | 55.4 | 0.106 | 94.73 | |
| Patients | 2 | 7.6 (0.0–32.2) | 48.3 | 0.164 | 5.27 | |
| Vaccine type | 0.319 | |||||
| BNT162b2 | 1 | 29.8 (0.0–71.2) | .. | .. | 0.01 | |
| Ad26.COV2.S | 1 | 0.1 (0.1–0.1) | .. | .. | 30.92 | |
| Any | 3 | 0.1 (0.1–0.2) | 92.4 | < 0.001 | 69.07 | |
| Population size | 0.158 | |||||
| < 1000 | 1 | 29.8 (0.0–71.2) | .. | .. | 0.01 | |
| > 100 000 | 4 | 0.1 (0.1–0.2) | 90.0 | < 0.001 | 99.9 | |
CI confidence interval